Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
An Evidence-based Staging System for Cutaneous Melanoma
391
Zitationen
18
Autoren
2004
Jahr
Abstract
A completely revised staging system for cutaneous melanoma was implemented in 2003. The changes were validated with a prognostic factors analysis involving 17,600 melanoma patients from prospective databases. This major collaborative study of predicting melanoma outcome was conducted specifically for this project, and the results were used to finalize the criteria for this evidence-based staging system. In fact, this was the largest prognostic factors analysis of prospectively followed melanoma patients ever conducted. Important results that shaped the staging criteria involved both the tumor-node-metastasis (TNM) criteria and stage grouping for all four stages of melanoma. Major changes in the staging include: (1) melanoma thickness and ulceration are the dominant predictors of survival in patients with localized melanoma (Stages I and II); deeper level of invasion (ie, IV and V) was independently associated with reduced survival only in patients with thin or T1 melanomas. (2) The number of metastatic lymph nodes and the tumor burden were the most dominant predictors of survival in patients with Stage III melanoma; patients with metastatic nodes detected by palpation had a shorter survival compared with patients whose nodal metastases were first detected by sentinel node excision of clinically occult or "microscopic" metastases. (3) The site of distant metastases (nonvisceral versus lung versus all other visceral metastatic sites) and the presence of elevated serum lactate dehydrogenase (LDH) were the dominant predictors of outcome in patients with Stage IV or distant metastases. (4) An upstaging was implemented for all patients with Stage I, II, and III disease when a primary melanoma is ulcerated by histopathological criteria. (5) Satellite metastases around a primary melanoma and in-transit metastases were merged into a single staging entity that is grouped into Stage III disease. (6) A new convention was implemented for defining clinical and pathological staging so as to take into account the new staging information gained from lymphatic mapping and sentinel node biopsy.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.418 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.106 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.664 Zit.
Final Version of 2009 AJCC Melanoma Staging and Classification
2009 · 4.558 Zit.
Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma
1992 · 4.401 Zit.
Autoren
Institutionen
- American Society of Clinical Oncology(US)
- University of Alabama at Birmingham(US)
- Clinical Research Management(US)
- Beth Israel Deaconess Medical Center(US)
- Atkins (United States)(US)
- Hospital Sírio-Libanês(BR)
- Memorial Sloan Kettering Cancer Center(US)
- University of Tennessee Health Science Center(US)
- The University of Texas MD Anderson Cancer Center(US)
- Houghton University(US)
- University of Pittsburgh Medical Center(US)
- University of Louisville(US)
- Harvard University(US)
- Massachusetts General Hospital(US)
- Saint John's Health Center(US)
- Regional Cancer Center(US)
- Lakeland Regional Medical Center(US)
- Royal Prince Alfred Hospital(AU)
- University of Sydney(AU)
- University of Washington Medical Center(US)